Gilead Sciences (GILD) Stock Price, Quote, News & History

Q: What sector and industry does Gilead Sciences (GILD) operate in?

Gilead Sciences is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.

Comments

Gilead Sciences (GILD) Stock Price, Quote, News & History

GILDNASDAQ

Logo brought to you by Benzinga Data

Trade with Public

$149.37

3.142.15%

At close: Feb 5, 4:00 PM EST

$151.95

2.581.73%

After Hours: 7:33 PM EST

Q4 2025 Earnings in 4 days from now on Tue Feb 10th, after the market close

Conference call scheduled in 4 days at 16:30 PMClick to view the webcast

Overview

News Earnings Options Guidance Dividends Analyst Ratings Insider Trades Short Interest Government Trades Stock Report

Edge Rankings

Stock Score Locked: Want to See it?

Benzinga Rankings give you vital metrics on any stock – anytime.

Reveal Full Score

Key Statistics

Open

$146.50

Close

$149.37

Volume / Avg.

9.14M / 7.21M

Day Range

$145.87 - $150.50

52 Wk Range

93.37 - 146.73

Market Cap

$188.52B

P/E Ratio

23.12

Dividend Yield

2.12%

Exchange

NASDAQ

RSI

82

Short Interest

1.87%

Days to Cover

3.66

Recent Gilead Sciences Inc News

Synopsys, Rocket Companies, On Holding And A Health Care Stock On CNBC's 'Final Trades'

Analysts expect Synopsys to report first-quarter earnings of approximately $3.56 per share on revenue of $2.39 billion.

Avi Kapoor

Medicare Targets 15 High-Profile Drugs In Third Price Negotiation Cycle

CMS selects 15 high-cost prescription drugs for Medicare drug price negotiation program, expanding to include Part B drugs.

Vandana Singh

The Insider Report: Bulls on Parade to Start 2026

Gianni di Poce

Financials

Quarterly

Annual

Name

Revenue Change
Gross Change
EBITDA Change
EBIT Change
Earnings Change

Cash Flows

Operating Cash Flow (TTM)

9.67B

Investing Cash Flow (TTM)

-3.18B

Financing Cash Flow (TTM)

-4.22B

Free Cash Flow (TTM)

9.16B

Capital Expenditure (TTM)

-505.00M

Net Change in Cash (TTM)

2.26B

Analyst Trends and Forecast

6

Oct 25

3

Nov 25

2

Dec 25

6

Jan

Buy

Hold

Sell

Strong Sell

Analyst Rating and Forecast

3.7

Buy

Strong Buy

Buy

Hold

Sell

Strong Sell

Valuation Metrics

Enterprise Value

$202.91B

PE Ratio (TTM)

23.12

PE Ratio (FWD)

17.01

PEG Ratio (TTM)

0.27

PS Ratio (TTM)

6.48

PB Ratio (TTM)

8.60

Earnings Yield % (TTM)

4.32%

Earnings Yield % (FWD)

5.88%

EV / EBITDA (TTM)

14.84

Price / EBITDA (TTM)

13.79

Price / Free Cash Flow (TTM)

20.57

Book Value / Share

$17.36

Company Debt

Total Debt

$24.94B

LT Debt

$22.14B

LT Debt Issuance (TTM)

-

LT Debt Repayment (TTM)

-$1.79B

Total Cash

$7.33B

Debt to Equity

1.16

Issuance of Debt (TTM)

$1.68B

Repayment of Debt (TTM)

-$1.79B

Key Statistics

Open

$146.50

Close

$149.37

Volume / Avg.

9.14M / 7.21M

Day Range

$145.87 - $150.50

52 Wk Range

93.37 - 146.73

Market Cap

$188.52B

P/E Ratio

23.12

Dividend Yield

2.12%

Exchange

NASDAQ

RSI

82

Short Interest

1.87%

Days to Cover

3.66

About

Sector

Health Care

Industry

Biotechnology

Gilead Sciences develops and markets therapies to treat and prevent life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Soval...

Compare

EPS better than industry

Earnings Per Share

EPS is the portion of a company's profit allocated to each outstanding share of common stock. It is a key metric for investors to assess a company's profitability.

Earnings Per Share

EPS is the portion of a company's profit allocated to each outstanding share of common stock. It is a key metric for investors to assess a company's profitability.

EPS better than industry

FAQ

Q

How do I buy Gilead Sciences (GILD) stock?

A

You can purchase shares of Gilead Sciences (NASDAQ:GILD) through any online brokerage.

View our list of the best stock brokerages

Q

Who are Gilead Sciences (GILD) competitors?

A

Other companies in Gilead Sciences’s space includes: Avidity Biosciences Inc (NASDAQ:RNA), Exact Sciences Corp (NASDAQ:EXAS), BeOne Medicines Ltd (NASDAQ:ONC), Neurocrine Biosciences Inc (NASDAQ:NBIX) and Ionis Pharmaceuticals Inc (NASDAQ:IONS).

Q

What is the forecast, or price target, for Gilead Sciences (GILD) stock?

A

Gilead Sciences has a consensus price target of $121.00.

Q

What is the current price for Gilead Sciences (GILD)?

A

The stock price for Gilead Sciences (NASDAQ: GILD) is $151.95 last updated February 5, 2026 at 7:33 PM EST.

Q

Does Gilead Sciences (GILD) pay a dividend?

A

There are no upcoming dividends for Gilead Sciences.

Q

When is Gilead Sciences (NASDAQ:GILD) reporting earnings?

A

Gilead Sciences does not have any upcoming earnings scheduled.

Q

Is Gilead Sciences (GILD) going to split?

A

There is no upcoming split for Gilead Sciences.

Q

What sector and industry does Gilead Sciences (GILD) operate in?

A

Gilead Sciences is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.

People Also Watch

Avidity Biosciences Inc

Neurocrine Biosciences Inc

NASDAQ:NBIX

$137.93

%

Ionis Pharmaceuticals Inc

United Therapeutics Corp

NASDAQ:UTHR

$478.93

%

Edge Rankings

Stock Score Locked: Want to See it?

Benzinga Rankings give you vital metrics on any stock – anytime.

Reveal Full Score

Key Statistics

Open

$146.50

Close

$149.37

Volume / Avg.

9.14M / 7.21M

Day Range

$145.87 - $150.50

52 Wk Range

93.37 - 146.73

Market Cap

$188.52B

P/E Ratio

23.12

Dividend Yield

2.12%

Exchange

NASDAQ

RSI

82

Short Interest

1.87%

Days to Cover

3.66

Recent Gilead Sciences Inc News

Synopsys, Rocket Companies, On Holding And A Health Care Stock On CNBC's 'Final Trades'

Analysts expect Synopsys to report first-quarter earnings of approximately $3.56 per share on revenue of $2.39 billion.

Avi Kapoor

Medicare Targets 15 High-Profile Drugs In Third Price Negotiation Cycle

CMS selects 15 high-cost prescription drugs for Medicare drug price negotiation program, expanding to include Part B drugs.

Vandana Singh

The Insider Report: Bulls on Parade to Start 2026

Gianni di Poce

Financials

Quarterly

Annual

Name

Revenue Change
Gross Change
EBITDA Change
EBIT Change
Earnings Change

Cash Flows

Operating Cash Flow (TTM)

9.67B

Investing Cash Flow (TTM)

-3.18B

Financing Cash Flow (TTM)

-4.22B

Free Cash Flow (TTM)

9.16B

Capital Expenditure (TTM)

-505.00M

Net Change in Cash (TTM)

2.26B

Analyst Trends and Forecast

6

Oct 25

3

Nov 25

2

Dec 25

6

Jan

Buy

Hold

Sell

Strong Sell

Analyst Rating and Forecast

3.7

Buy

Strong Buy

Buy

Hold

Sell

Strong Sell

Valuation Metrics

Enterprise Value

$202.91B

PE Ratio (TTM)

23.12

PE Ratio (FWD)

17.01

PEG Ratio (TTM)

0.27

PS Ratio (TTM)

6.48

PB Ratio (TTM)

8.60

Earnings Yield % (TTM)

4.32%

Earnings Yield % (FWD)

5.88%

EV / EBITDA (TTM)

14.84

Price / EBITDA (TTM)

13.79

Price / Free Cash Flow (TTM)

20.57

Book Value / Share

$17.36

Company Debt

Total Debt

$24.94B

LT Debt

$22.14B

LT Debt Issuance (TTM)

-

LT Debt Repayment (TTM)

-$1.79B

Total Cash

$7.33B

Debt to Equity

1.16

Issuance of Debt (TTM)

$1.68B

Repayment of Debt (TTM)

-$1.79B

Key Statistics

Open

$146.50

Close

$149.37

Volume / Avg.

9.14M / 7.21M

Day Range

$145.87 - $150.50

52 Wk Range

93.37 - 146.73

Market Cap

$188.52B

P/E Ratio

23.12

Dividend Yield

2.12%

Exchange

NASDAQ

RSI

82

Short Interest

1.87%

Days to Cover

3.66

About

Sector

Health Care

Industry

Biotechnology

Gilead Sciences develops and markets therapies to treat and prevent life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Soval...

Compare

EPS better than industry

Earnings Per Share

EPS is the portion of a company's profit allocated to each outstanding share of common stock. It is a key metric for investors to assess a company's profitability.

Earnings Per Share

EPS is the portion of a company's profit allocated to each outstanding share of common stock. It is a key metric for investors to assess a company's profitability.

EPS better than industry